Related Videos
ESMO25 Breast Cancer Highlights: ASCENT-03 and TROPION-Breast02
Harold Burstein, MD, PhD, and Ana Garrido- Castro, MD, discuss the ASCENT-03 and TROPION-Breast02 trials, investigating antibody-drug conjugates for triple-negative breast cancer.
Ana Garrido-Castro, MD Discusses SACI-IO HR+
Antibody-drug conjugate plus a checkpoint inhibitor shows a trend toward improved survival in PD-L1-positive hormone receptor-positive, HER2-negative breast cancer.
